The immune checkpoint inhibitors (ICI) such as anti-CTLA-4 antibody as well as anti-PD-1, have revolutionized the treatment of several cancers but fail to control cancer progression in a significant proportion of patients (102–104). The gene discussed is CTLA4; the disease is cancer.